Beacon Medical Interchange is a venture founded in 2016 by Dr. Jack West to facilitate communication of medical experts with industry leaders on the evolution of medical care trends in general and cancer management in particular.
Focusing on issues ranging from behavioral economics and decision-making based on emerging data to trends such as telemedicine, social media, and the growing role of algorithm-based interventions, Dr. West facilitates data collection and moderates interactive meetings, advisory boards, producing summary reports of current and projected market analysis.
To discuss potential new programs or sponsorship/participation in current ones, please contact Dr. West.
Recent Beacon Media Posts
Dr. Daniel Goldstein summarizes key data in genitourinary oncology from ASCO 2018, including new results on pembrolizumab (Keytruda) for metastatic prostate cancer, asking whether it could find a place as treatment for a subset of these patients. (2:17)
Dr. Daniel Goldstein reviews data from ASCO 2018 on patient-reported quality of life on atezolizumab/bevacizumab compared to sunitinib in metastatic kidney cancer, along with the context of other treatment options in this setting. (2:18)
Dr. Daniel Goldstein discusses the results of a trial of first line pembrolizumab (Keytruda) as first line therapy for patients with metastatic clear cell renal cell carcinoma and the implications for the future role of immunotherapy in RCC. (3:18)